Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™
16 November 2018 - 1:30PM
Imprimis attributes growth to its vision of
making sure patients have access to high quality affordable
medications
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced that
it ranked 88th on Deloitte’s Technology Fast 500™, a ranking of the
500 fastest growing technology, media, telecommunications, life
sciences and energy tech companies in North America. Winners
were selected based on percentage fiscal year revenue growth from
2014 to 2017, and Imprimis grew 1,513% during this period.
Mark L. Baum, CEO of Imprimis, stated, “I am
proud of the work we have continued to do and the growth we’ve
experienced since first being included on the Fast 500 list two
years ago. In 2014, we launched our ophthalmology business
and from 2014 to 2017 we’ve seen ophthalmology revenue grow at a
compounded annual growth rate of 238%. Customers show their
trust with their dollars, and given our fast growth, our focus on
access to high quality affordable medicines is being rewarded
through the trust of thousands of physicians across the country who
rely on our innovative formulations to care for their
patients. I want to thank the hard-working employees of
Imprimis, our physician partners, our dedicated customers, and our
loyal shareholders, all of whom allow us to continue to help take
great care of the health of thousands of Americans each day.”
“Congratulations to the Deloitte 2018 Technology
Fast 500 winners on this impressive achievement,” said Sandra
Shirai, vice chairman, Deloitte LLP, and U.S. technology, media and
telecommunications leader. “These companies are innovators who have
converted their disruptive ideas into products, services and
experiences that can captivate new customers and drive remarkable
growth.”
Imprimis Pharmaceuticals previously ranked 12th
as a Technology Fast 500™ award winner for 2016.
About Deloitte’s 2018 Technology Fast
500™
Deloitte’s Technology Fast 500 provides a ranking of the fastest
growing technology, media, telecommunications, life sciences and
energy tech companies — both public and private — in North America.
Technology Fast 500 award winners are selected based on percentage
fiscal year revenue growth from 2014 to 2017.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least $50,000 USD, and current-year
operating revenues of at least $5 million USD. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North America.
About Imprimis
Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY)
owns a diversified portfolio of healthcare businesses, including
the nation’s leading ophthalmology pharmaceutical compounding
business, ImprimisRx. The company also holds large equity
positions in Eton Pharmaceuticals (NASDAQ: ETON), Surface
Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and
Radley Pharmaceuticals, companies founded as subsidiaries of
Imprimis. The Company also owns royalty rights in certain
505(b)(2) drug candidates being developed by Eton, Surface, Melt,
Mayfield and Radley. For more information about Imprimis,
please visit the Investor Relations section of the corporate
website by clicking here.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu
Limited, a UK private company limited by guarantee (“DTTL”), its
network of member firms, and their related entities. DTTL and each
of its member firms are legally separate and independent entities.
DTTL (also referred to as “Deloitte Global”) does not provide
services to clients. In the United States, Deloitte refers to one
or more of the US member firms of DTTL, their related entities that
operate using the “Deloitte” name in the United States and their
respective affiliates. Certain services may not be available to
attest clients under the rules and regulations of public
accounting. Please see www.deloitte.com/about to learn more
about our global network of member firms.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Imprimis' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. Undue reliance should not be placed
on forward-looking statements, which speak only as of the date they
are made. Except as required by law, Imprimis undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events.
No Imprimis compounded formulation is
FDA-approved. Other than drugs compounded at a registered
outsourcing facility, all Imprimis compounded formulations require
a prescription for an individually identified patient consistent
with federal and state laws.
Investor ContactJon Patton
jpatton@imprimispharma.com 858.704.4587
Media ContactDeb HollidayHolliday
Communications, Inc.deb@hollidaycommunications.net412.877.4519
Source: Imprimis Pharmaceuticals, Inc.
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
Von Jun 2023 bis Jun 2024